NewAmsterdam Pharma Co. N.V. (NAMS) intrinsic value & 10-year financials
NewAmsterdam Pharma Co. N.V. (NAMS) has a Graham intrinsic value of $105.24 per share. At $19.83 on Oct 17, 2026, the stock trades 81% below that value. Over the last 6 fiscal years revenue shrank 39.7% a year to $22.5M, with an average return on invested capital of 324.0%.
- Graham intrinsic value
- $105.24
- Share price (Oct 17, 2026)
- $19.83
- Price vs Graham value
- 81% below
- Market cap
- $2.3B
- Revenue (FY2025)
- $22.5M
- Revenue growth (6-yr CAGR)
- -39.7%
- ROIC (10-yr avg)
- 324.0%
- Free cash flow (FY2025)
- -$148.0M
NAMS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $22.5M | -$203.8M | -$1.72 | -$148.0M | -1002.9% | -227.2% |
| FY2024 | $45.6M | -$241.6M | -$2.56 | -$159.2M | -386.9% | 1255.5% |
| FY2023 | $14.1M | -$176.9M | -$2.15 | -$141.2M | -1298.6% | 486.6% |
| FY2022 | $102.7M | -$22.6M | -$1.19 | $10.4M | -3.5% | 60.2% |
| FY2021 | — | -$41.8M | -$3.81 | -$29.5M | — | 44.7% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NewAmsterdam Pharma Co N.V. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NewAmsterdam Pharma Co N.V. has earned high returns on invested capital, averaging 24.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
NewAmsterdam Pharma Co N.V. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NewAmsterdam Pharma Co N.V. is modeled at -39.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $105.24 per share.